한국의 염증성 장질환과 자가면역성 간염 환자에서 Azathioprine의 부작용 비교
- Author(s)
- 이유진; 최왕용; 박경식; 김윤정; 조광범; 김은수; 장병국; 정우진; 황재석
- Keimyung Author(s)
- Lee, Yoo Jin; Park, Kyung Sik; Cho, Kwang Bum; Kim, Eun Soo; Jang, Byoung Kuk; Chung, Woo Jin; Hwang, Jae Seok
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Korean journal of gastroenterology
- Issued Date
- 2014
- Volume
- 64
- Issue
- 6
- Abstract
- Background/Aims: Azathioprine (AZA) has been widely used in the therapy of inflammatory bowel disease (IBD) and autoimmune
hepatitis (AIH). However, studies evaluating the adverse effects of AZA in these two diseases are lacking. The aim of this
study was to compare the adverse effects of AZA in Korean IBD and AIH patients.
Methods: Patients with IBD or AIH who were treated with AZA at Keimyung University Dongsan Medical Center (Daegu, Korea)
between January 2002 and March 2011 were enrolled. Their medical records were reviewed retrospectively in terms of clinical
characteristics and adverse effects of AZA.
Results: A total of 139 IBD patients and 55 AIH patients were finally enrolled. Thirty IBD patients (21.6%) and eight AIH
patients (14.5%) experienced adverse effects of AZA. In particular, the prevalence of leukopenia was significantly higher in
the IBD group than in the AIH group (p=0.026). T474C mutation was observed in three of 10 patients who were assessed
for thiopurine methyltransferase (TPMT) genotype.
Conclusions: IBD patients are at increased risk for the adverse effects of AZA compared with AIH patients, of which leukopenia
was the most commonly observed. Therefore, IBD patients receiving AZA therapy should be carefully monitored. (Korean J
Gastroenterol 2014;64:348-355)
Key Words: Azathioprine; Inflammatory bowel diseases; Hepatitis, autoimmune; Adverse effects
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.